Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Med Arh. 2008;62(3):175-6.

[Case report of successful treating of refractory form of chronic lymphatic leukemia in Binnet C stage by using anti-CD52 antibodies].

[Article in Bosnian]

Author information

  • 1Hematoloski odjel Klinike za interne bolesti, UKC Tuzla.


Chronic lymphatic leukemia (CLL) is the most frequent type of leukemia in western world, and a choice of treatment modality depends on current stage of disease. Clinical condition of patient considered as Binnet C stage, requires treatment. Standard polyhemiotherapy (FC protocol) does not always warrant adequate and satisfactory response. This case report reviews the patient with CLL in Binnet C stage, who did not respond on FC protocol in expected way, meaning, hematological and medullar response was not detected. Twelve weeks therapy of monoclonal antiCD52 antibody (MabCampath) was than applied, resulting in normalization of all parameters of disease activity, which was desired effect of the therapy. Administration of monoclonal antiCD52 antibody is justified in case of resistance on conventional previously applied means of therapy.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk